Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Align TechnologyZimmer BiometEdwards LifesciencesColoplast A/SSmith & Nephew
SymbolNASDAQ:ALGNNYSE:ZBHNYSE:EWOTCMKTS:CLPBYNYSE:SNN
Price Information
Current Price$592.56$169.48$85.99$15.57$38.50
52 Week RangeBuyBuyBuyHoldHold
MarketRank™
Overall Score1.92.11.41.02.1
Analysis Score2.32.51.30.03.2
Community Score2.82.83.02.21.9
Dividend Score0.01.70.01.72.5
Ownership Score1.71.71.70.00.0
Earnings & Valuation Score2.51.91.31.33.1
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldHold
Consensus Price Target$501.33$165.59$91.54N/A$47.17
% Upside from Price Target-15.40% downside-2.29% downside6.46% upsideN/A22.51% upside
Trade Information
Market Cap$46.89 billion$35.31 billion$53.49 billion$33.24 billion$16.92 billion
Beta1.681.340.970.280.7
Average Volume638,0371,255,4132,673,350109,886419,923
Sales & Book Value
Annual Revenue$2.41 billion$7.98 billion$4.35 billion$2.76 billion$5.14 billion
Price / Sales19.484.4212.3012.173.29
Cashflow$6.49 per share$15.68 per share$1.96 per share$0.30 per share$2.84 per share
Price / Cash91.2910.8143.9052.4713.55
Book Value$17.08 per share$60.25 per share$6.63 per share$0.48 per share$11.76 per share
Price / Book34.692.8112.9732.443.27
Profitability
Net Income$442.78 million$1.13 billion$1.05 billion$585.21 million$600 million
EPS$4.96$7.87$1.86$0.30$2.04
Trailing P/E Ratio26.961,059.3268.7955.6118.87
Forward P/E Ratio83.2221.4540.3743.2519.95
P/E Growth4.074.322.61N/A4.91
Net Margins76.00%0.52%18.18%21.62%N/A
Return on Equity (ROE)68.99%10.07%29.00%69.30%N/A
Return on Assets (ROA)46.64%4.93%18.10%33.77%N/A
Dividend
Annual PayoutN/A$0.96N/A$0.22$0.90
Dividend YieldN/A0.57%N/A1.41%2.34%
Three-Year Dividend GrowthN/AN/AN/AN/A102.70%
Payout RatioN/A12.20%N/A73.33%44.12%
Years of Consecutive Dividend GrowthN/A1 YearsN/AN/A1 Years
Debt
Debt-to-Equity RatioN/A0.67%0.14%0.02%0.50%
Current Ratio1.31%2.18%3.52%1.29%2.18%
Quick Ratio1.20%1.02%2.61%0.90%1.04%
Ownership Information
Institutional Ownership Percentage85.84%87.17%80.94%0.10%8.91%
Insider Ownership Percentage1.20%0.44%1.48%N/A1.00%
Miscellaneous
Employees18,07019,90014,90012,50018,000
Shares Outstanding79.13 million208.32 million622.04 million2.16 billion439.44 million
Next Earnings Date4/28/2021 (Confirmed)5/4/2021 (Confirmed)4/20/2021 (Confirmed)N/AN/A
OptionableOptionableOptionableOptionableNot OptionableOptionable
SourceHeadline
Smith & Nephew PLC Stock Shows Every Sign Of Being Fairly ValuedSmith & Nephew PLC Stock Shows Every Sign Of Being Fairly Valued
finance.yahoo.com - April 2 at 1:27 PM
Smith & Nephew (NYSE:SNN) Receives "Overweight" Rating from BarclaysSmith & Nephew (NYSE:SNN) Receives "Overweight" Rating from Barclays
americanbankingnews.com - March 31 at 4:26 PM
Barclays Reiterates Overweight Rating for Smith & Nephew (NYSE:SNN)Barclays Reiterates Overweight Rating for Smith & Nephew (NYSE:SNN)
marketbeat.com - March 31 at 4:25 PM
Smith & Nephew plc (NYSE:SNN) Receives Average Rating of "Hold" from BrokeragesSmith & Nephew plc (NYSE:SNN) Receives Average Rating of "Hold" from Brokerages
americanbankingnews.com - March 25 at 8:54 AM
Smith & Nephew plc (NYSE:SNN) Sees Significant Growth in Short InterestSmith & Nephew plc (NYSE:SNN) Sees Significant Growth in Short Interest
americanbankingnews.com - March 17 at 5:28 PM
How Does Smith & Nephews Debt Look?How Does Smith & Nephew's Debt Look?
finance.yahoo.com - March 15 at 12:42 PM
UPDATE 1-U.S. Supreme Court questions patent tribunals constitutionalityUPDATE 1-U.S. Supreme Court questions patent tribunal's constitutionality
finance.yahoo.com - March 1 at 3:32 PM
Berenberg lowers target price on Smith & NephewBerenberg lowers target price on Smith & Nephew
lse.co.uk - February 22 at 2:11 PM
MARKET REPORT: Cancelled surgeries bring pain to Smith & NephewMARKET REPORT: Cancelled surgeries bring pain to Smith & Nephew
msn.com - February 18 at 6:57 PM
Medical equipment firm Smith & Nephews profits hit as hospitals postpone surgeries to treat Covid patientsMedical equipment firm Smith & Nephew's profits hit as hospitals postpone surgeries to treat Covid patients
msn.com - February 18 at 8:56 AM
John Ma joins Smith+Nephews Board as NEDJohn Ma joins Smith+Nephew's Board as NED
sharecast.com - February 11 at 10:22 PM
Smith & Nephew Plc - John Ma joins Smith+Nephews Board as NEDSmith & Nephew Plc - John Ma joins Smith+Nephew's Board as NED
proactiveinvestors.co.uk - February 10 at 8:21 AM
Integra (IART) to Buy ACell, Expand Regenerative CapabilityIntegra (IART) to Buy ACell, Expand Regenerative Capability
nasdaq.com - December 29 at 1:34 PM
Is SNN A Good Stock To Buy Now?Is SNN A Good Stock To Buy Now?
finance.yahoo.com - December 10 at 8:26 PM
New data shows Smith+Nephews NOVOSTITCH™ Meniscal Repair Systems achieve 82.6% success rate for difficult to repair¹ horizontal cleavage tears at two years follow-upNew data shows Smith+Nephew's NOVOSTITCH™ Meniscal Repair Systems achieve 82.6% success rate for difficult to repair¹ horizontal cleavage tears at two years follow-up
finance.yahoo.com - November 17 at 8:08 AM
There’s no need to share Soros’s pain with Smith & NephewThere’s no need to share Soros’s pain with Smith & Nephew
thetimes.co.uk - November 12 at 5:17 AM
Smith & Nephew Holds The Line, But So Does Our ThesisSmith & Nephew Holds The Line, But So Does Our Thesis
seekingalpha.com - November 9 at 12:29 PM
Smith+Nephew adds patient selection and care-pathway optimization tools to ARIA Digital Care Management Platform for ASCsSmith+Nephew adds patient selection and care-pathway optimization tools to ARIA Digital Care Management Platform for ASCs
finance.yahoo.com - November 5 at 8:22 AM
Smith & Nephew sales improve in Q3, US business returns to growthSmith & Nephew sales improve in Q3, US business returns to growth
sharecast.com - October 29 at 7:16 PM
NASAs OSIRIS-REx just snatched a rock sample from asteroid BennuNASA's OSIRIS-REx just snatched a rock sample from asteroid Bennu
techcrunch.com - October 22 at 5:52 PM
Smith & Nephew Buys Integra’s Extremities Business for $240 MillionSmith & Nephew Buys Integra’s Extremities Business for $240 Million
ryortho.com - October 8 at 1:19 PM
J&J Cos. Sue To Block Execs Move To Smith & NephewJ&J Cos. Sue To Block Exec's Move To Smith & Nephew
law360.com - October 2 at 2:52 PM
Smith & Nephew on the mend as routine surgery starts againSmith & Nephew on the mend as routine surgery starts again
thetimes.co.uk - October 2 at 2:52 PM
Smith & Nephew revenue slide to slow in third quarterSmith & Nephew revenue slide to slow in third quarter
uk.reuters.com - October 1 at 7:29 AM
Smith & Nephew agrees orthopaedics buyoutSmith & Nephew agrees orthopaedics buyout
thetimes.co.uk - September 30 at 2:46 PM
Smith+Nephew to buy Integra extremities business to for $240MSmith+Nephew to buy Integra extremities business to for $240M
massdevice.com - September 29 at 1:06 PM
DateCompanyBrokerageAction
2/4/2021Align TechnologyEvercore ISIBoost Price Target
2/4/2021Align TechnologyCredit Suisse GroupBoost Price Target
2/4/2021Align TechnologySVB LeerinkBoost Price Target
2/4/2021Align TechnologyBarclaysBoost Price Target
2/2/2021Align TechnologyPiper SandlerBoost Price Target
11/24/2020Align TechnologyThe Goldman Sachs GroupBoost Price Target
11/24/2020Align TechnologyRobert W. BairdBoost Price Target
10/28/2020Align TechnologyStifel NicolausBoost Price Target
10/22/2020Align TechnologyJefferies Financial GroupBoost Price Target
7/29/2020Align TechnologyBerenberg BankDowngrade
7/20/2020Align TechnologyBank of AmericaDowngrade
4/9/2021Zimmer BiometNorthland SecuritiesUpgrade
3/8/2021Zimmer BiometOppenheimerBoost Price Target
3/8/2021Zimmer BiometWells Fargo & CompanyBoost Price Target
2/8/2021Zimmer BiometMorgan StanleyBoost Price Target
2/8/2021Zimmer BiometRaymond JamesBoost Price Target
2/8/2021Zimmer BiometDeutsche Bank AktiengesellschaftBoost Price Target
2/5/2021Zimmer BiometNeedham & Company LLCBoost Price Target
1/27/2021Zimmer BiometJMP SecuritiesBoost Price Target
1/25/2021Zimmer BiometBTIG ResearchBoost Price Target
1/6/2021Zimmer BiometTruist FinancialBoost Price Target
12/24/2020Zimmer BiometArgusBoost Price Target
12/16/2020Edwards LifesciencesSmith Barney CitigroupDowngrade
12/16/2020Edwards LifesciencesCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngrade
12/11/2020Edwards LifesciencesCanaccord GenuityBoost Price Target
10/19/2020Edwards LifesciencesCowenBoost Price Target
9/11/2020Edwards LifesciencesWolfe ResearchInitiated Coverage
3/9/2021Coloplast A/SCommerzbankUpgrade
2/9/2021Coloplast A/SJPMorgan Chase & Co.Reiterated Rating
8/11/2020Coloplast A/SNordea Equity ResearchDowngrade
12/18/2020Smith & NephewSanford C. BernsteinUpgrade
6/5/2020Smith & NephewBNP ParibasDowngrade
6/5/2020Smith & NephewExane BNP ParibasDowngrade
(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.